Provided by Tiger Trade Technology Pte. Ltd.

BlossomHill Therapeutics

16.38
+0.58003.67%
Post-market: 16.380.00000.00%19:30 EDT
Volume:111.39K
Turnover:1.81M
Market Cap:501.94M
PE:-6.70
High:16.50
Open:16.00
Low:15.75
Close:15.80
52wk High:17.25
52wk Low:15.25
Shares:30.64M
Float Shares:9.38M
Volume Ratio:0.45
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4440
EPS(LYR):-24.8342
ROE:--
ROA:--
PB:-3.30
PE(LYR):-0.66

Loading ...

Company Profile

Company Name:
BlossomHill Therapeutics
Exchange:
NASDAQ
Establishment Date:
2020
Employees:
- -
Office Location:
10255 Science Center Drive,Suite 200,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
BlossomHill Therapeutics, Inc. was incorporated in Delaware on June 22, 2020. The company is a clinical-stage biopharmaceutical company that applies chemistry-based rational drug design approaches to develop innovative small molecule drugs addressing significant unmet medical needs in cancer treatment. Its scientific founders and team have a proven track record in developing innovative small molecule drugs that overcome the limitations of existing therapies, including multiple approved therapies that have delivered transformative patient outcomes.

Directors

Name
Position
J. Jean Cui
Chief Executive Officer and Director and President
Y. Peter Li
Executive Chairman and Director
Bihua Chen
Director
Carl L. Gordon
Director
John Schmid
Director
Sheila Gujrathi
Director
Sundeep Agrawal
Director
Timothy Stubbs
Director

Shareholders

Name
Position
J. Jean Cui
Chief Executive Officer and Director and President
Jason Keyes
Chief Financial Officer and Executive Vice President
Geoff Oxnard
Chief Medical Officer and Executive Vice President
Vincent Liptak
Executive Vice President and General Counsel
Y. Peter Li
Executive Chairman and Director